Better Choice Company Appoints Renowned Expert in Rare and Undiagnosed Diseases, Dr. Paldeep S. Atwal, as its United States Special Healthcare Advisor
Better Choice Company (NYSE: BTTR) has appointed Dr. Paldeep S. Atwal as its United States Special Healthcare Advisor. Dr. Atwal, a board-certified clinical and medical biochemical geneticist, brings extensive expertise in rare diseases and genomic medicine to the pet health and wellness company.
Dr. Atwal is the founder of Atwal Clinic for Genomic & Personalized Medicine in Palm Beach, FL, and previously served as Medical Director at both Everly Health Solutions and Mayo Clinic Florida's Individualized Medicine Clinic. The appointment comes as Better Choice approaches the completion of its SRx Health acquisition.
Chairman Michael Young emphasized that Dr. Atwal's expertise will be important for accelerating company growth, particularly in developing new offerings and strategic healthcare partnerships. Dr. Atwal's background includes notable achievements such as the ACMG Foundation/Genzyme Fellowship and training at prestigious institutions including Stanford University and Baylor College of Medicine.
Better Choice Company (NYSE: BTTR) ha nominato Dr. Paldeep S. Atwal come suo Consulente Speciale per la Salute negli Stati Uniti. Il Dr. Atwal, un genetista clinico e biochimico certificato, porta una vasta esperienza nelle malattie rare e nella medicina genomica all'azienda che si occupa della salute e del benessere degli animali domestici.
Il Dr. Atwal è il fondatore dell'Atwal Clinic per la Medicina Genomica e Personalizzata a Palm Beach, FL, e ha precedentemente ricoperto il ruolo di Direttore Medico sia presso Everly Health Solutions che presso la Clinica di Medicina Individualizzata della Mayo Clinic in Florida. Questa nomina arriva mentre Better Choice si avvicina al completamento dell'acquisizione di SRx Health.
Il presidente Michael Young ha sottolineato che l'expertise del Dr. Atwal sarà fondamentale per accelerare la crescita dell'azienda, in particolare nello sviluppo di nuove offerte e alleanze strategiche nel settore sanitario. Il background del Dr. Atwal include risultati notevoli come la Fellowship della ACMG Foundation/Genzyme e la formazione presso istituzioni prestigiose come la Stanford University e il Baylor College of Medicine.
Better Choice Company (NYSE: BTTR) ha nombrado al Dr. Paldeep S. Atwal como su Asesor Especial en Salud para Estados Unidos. El Dr. Atwal, un genetista clínico y bioquímico certificado, aporta una amplia experiencia en enfermedades raras y medicina genómica a la empresa de salud y bienestar de mascotas.
El Dr. Atwal es el fundador de la Atwal Clinic para Medicina Genómica y Personalizada en Palm Beach, FL, y anteriormente se desempeñó como Director Médico en Everly Health Solutions y en la Clínica de Medicina Individualizada de Mayo Clinic Florida. Esta designación se produce mientras Better Choice se acerca a la finalización de su adquisición de SRx Health.
El presidente Michael Young enfatizó que la experiencia del Dr. Atwal será importante para acelerar el crecimiento de la empresa, particularmente en el desarrollo de nuevas ofertas y asociaciones estratégicas en salud. El historial del Dr. Atwal incluye logros notables como la Beca de la ACMG Foundation/Genzyme y formación en instituciones de prestigio, incluyendo la Universidad de Stanford y el Baylor College of Medicine.
Better Choice Company (NYSE: BTTR)는 Dr. Paldeep S. Atwal을 미국 특별 의료 고문으로 임명했습니다. Atwal 박사는 보드 인증을 받은 임상 및 의학 생화학 유전학자로서, 희귀 질환 및 유전체 의학에 대한 광범위한 전문 지식을 반려동물 건강 및 웰빙 회사에 제공합니다.
Atwal 박사는 플로리다주 팜 비치에 위치한 Atwal Clinic for Genomic & Personalized Medicine의 창립자이며, 이전에는 Everly Health Solutions와 Mayo Clinic Florida의 개인 맞춤형 의학 클리닉에서 의료 이사로 근무했습니다. 이번 임명은 Better Choice가 SRx Health 인수 완료에 가까워지면서 이루어졌습니다.
회장인 Michael Young은 Atwal 박사의 전문 지식이 회사 성장 가속화에 중요할 것이라고 강조하며, 특히 새로운 서비스 개발 및 전략적 의료 파트너십 구축에 기여할 것이라고 말했습니다. Atwal 박사는 ACMG Foundation/Genzyme Fellowship 및 스탠포드 대학교와 베일러 의과대학과 같은 저명한 기관에서의 교육을 포함한 주목할 만한 업적을 보유하고 있습니다.
Better Choice Company (NYSE: BTTR) a nommé Dr. Paldeep S. Atwal en tant que Conseiller Spécial en Santé pour les États-Unis. Le Dr Atwal, généticien clinique et biochimiste médical certifié, apporte une vaste expertise dans les maladies rares et la médecine génomique à l'entreprise de santé et de bien-être animal.
Le Dr Atwal est le fondateur de l'Atwal Clinic pour la Médecine Génomique et Personnalisée à Palm Beach, FL, et a précédemment occupé le poste de Directeur Médical chez Everly Health Solutions et à la Clinique de Médecine Individualisée de la Mayo Clinic en Floride. Cette nomination intervient alors que Better Choice s'approche de l'achèvement de son acquisition de SRx Health.
Le président Michael Young a souligné que l'expertise du Dr Atwal sera importante pour accélérer la croissance de l'entreprise, en particulier dans le développement de nouvelles offres et de partenariats stratégiques en santé. Le parcours du Dr Atwal comprend des réalisations notables telles que la Bourse de la Fondation ACMG/Genzyme et une formation dans des institutions prestigieuses comme l'Université de Stanford et le Baylor College of Medicine.
Better Choice Company (NYSE: BTTR) hat Dr. Paldeep S. Atwal zu seinem speziellen Gesundheitsberater für die Vereinigten Staaten ernannt. Dr. Atwal, ein zertifizierter klinischer und medizinischer biochemischer Genetiker, bringt umfangreiche Expertise in seltenen Krankheiten und Genommedizin in das Unternehmen für Tiergesundheit und -wohlbefinden ein.
Dr. Atwal ist der Gründer der Atwal Clinic für Genomische und Personalisierte Medizin in Palm Beach, FL, und war zuvor medizinischer Direktor bei Everly Health Solutions und der Individualisierten Medizin Klinik der Mayo Clinic in Florida. Die Ernennung erfolgt, während Better Choice dem Abschluss seiner SRx Health-Akquisition näherkommt.
Vorsitzender Michael Young betonte, dass Dr. Atwals Expertise wichtig sein wird, um das Unternehmenswachstum zu beschleunigen, insbesondere bei der Entwicklung neuer Angebote und strategischer Gesundheitspartnerschaften. Dr. Atwals Hintergrund umfasst bemerkenswerte Errungenschaften wie das ACMG Foundation/Genzyme Fellowship und eine Ausbildung an renommierten Institutionen wie der Stanford University und dem Baylor College of Medicine.
- Strategic appointment of healthcare expert as company approaches SRx Health acquisition
- Addition of renowned medical expertise to support expansion into health and wellness offerings
- Potential for new strategic healthcare partnerships
- None.
TAMPA, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, today announced the appointment of Dr. Paldeep S. Atwal as its United States Special Healthcare Advisor.
Renowned for his expertise in rare and undiagnosed diseases, Dr. Atwal has dedicated his career to advancing the field of genomic medicine through cutting-edge diagnostics, research, and patient care. Dr. Atwal is a board-certified clinical and medical biochemical geneticist and the founder of Atwal Clinic for Genomic & Personalized Medicine, a premier private genetics clinic in Palm Beach, FL. Previously, he served as Medical Director of Genetic Services at Everly Health Solutions (formerly PWNHealth), a leading virtual healthcare company, and as Medical Director for the Individualized Medicine Clinic at Mayo Clinic in Florida, where he played a pivotal role in advancing precision medicine initiatives.
"As we near the closing of our acquisition of SRx Health, it is critical we continue to build our team with healthcare professionals and experts such as Dr. Atwal," said Michael Young, Chairman of Better Choice. "Dr. Atwal’s appointment will be key in accelerating the our growth, particularly in new offerings, strategic healthcare partnerships, and aligning with the evolving wellness and preventative health landscape. Dr. Atwal's pioneering work in genomic medicine, combined with his vast expertise in rare diseases and personalized care, will be invaluable as we continue to innovate and expand our health and wellness offerings. His strategic vision will be instrumental in shaping our future initiatives and ensuring we lead the way in delivering impactful health solutions that truly improve lives."
As a recognized leader in genomic medicine, Dr. Atwal is committed to advancing personalized, science-driven care, with his pioneering contributions earning numerous prestigious awards, including the ACMG Foundation/Genzyme Fellowship, and the Neurobiology of Disease in Children Young Investigator Award. Dr. Atwal earned his medical degree from the University of Glasgow and trained in internal medicine at Glasgow Royal Infirmary with the Royal College of Physicians. He also pursued a genetics fellowship at Stanford University and a sub-specialty biochemical genetics fellowship at Baylor College of Medicine, where he contributed to the development of a clinical metabolomic profiling test.
About Better Choice Company Inc.
Better Choice Company Inc. is a rapidly growing pet health and wellness company committed to leading the industry shift toward pet products and services that help dogs and cats live healthier, happier, and longer lives. We take an alternative, nutrition-based approach to pet health relative to conventional dog and cat food offerings and position our portfolio of brands to benefit from the mainstream trends of growing pet humanization and consumer focus on health and wellness. We have a demonstrated, multi-decade track record of success selling trusted pet health and wellness products and leverage our established digital footprint to provide pet parents with the knowledge to make informed decisions about their pet’s health. We sell the majority of our dog food, cat food and treats under the Halo brand, which is focused, respectively, on providing sustainably sourced kibble and canned food derived from real whole meat, and minimally processed raw-diet dog food and treats. For more information, please visit https://www.betterchoicecompany.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company’s risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
Better Choice Company, Inc.
Kent Cunningham, CEO
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
T: 212-896-1254
Valter@KCSA.com
FAQ
What is the significance of Dr. Atwal's appointment for Better Choice Company (BTTR)?
What are Dr. Atwal's key credentials and experience before joining BTTR?
How does Dr. Atwal's expertise align with Better Choice's future strategy?
What major acquisition is Better Choice (BTTR) currently finalizing?
